Century Therapeutics (IPSC) Stock Price, News & Analysis

Company Overview

Century Therapeutics, Inc. (NASDAQ:IPSC) is a biotechnology company developing allogeneic cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create potentially scalable immune-cell products designed to treat patients without relying on cells collected from each individual patient.

Century’s research focuses primarily on iPSC-derived natural killer (NK) cells and T cells that are genetically engineered to recognize and attack cancer cells. Its pipeline has included investigational chimeric antigen receptor (CAR) cell therapies targeting blood cancers, including B-cell malignancies, with the goal of providing readily available, “off-the-shelf” treatments.

Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics conducts research and development activities in the United States. Its therapies remain investigational and are subject to clinical testing and regulatory review before they can be broadly marketed.

Key Stats

• Today's Range: $1.35 to $1.44
• 50-Day Range: $1.28 to $2.23
• 52-Week Range: $0.44 to $3.04
• Volume: 544,250 shs
• Average Volume: 754,298 shs
• Market Capitalization: $249.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.75
• Consensus Rating: Hold

Century Therapeutics Stock Analysis - MarketRank™

Century Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 699th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Century Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Century Therapeutics has a consensus price target of $4.75, representing about 244.2% upside from its current price of $1.38.

Amount of Analyst Coverage

Century Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Century Therapeutics are expected to remain at ($0.51) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Century Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Century Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Century Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.53% of the float of Century Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Century Therapeutics has a short interest ratio ("days to cover") of 50.91, which indicates bearish sentiment.

Change versus previous month

Short interest in Century Therapeutics has recently decreased by 0.46%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Century Therapeutics does not currently pay a dividend.

Dividend Growth

Century Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.61

News Sentiment

Century Therapeutics has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Century Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,808.00 in company stock.

Percentage Held by Insiders

2.40% of the stock of Century Therapeutics is held by insiders.

Percentage Held by Institutions

50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IPSC
• CIK: 1850119
• Web: www.centurytx.com
• Phone: 267-817-5790
• Fax: N/A
• Employees: 78
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Century Therapeutics: $4.75
• High Price Target: $8.00
• Low Price Target: $2.00
• Potential Upside/Downside: +244.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.51%
• Return on Assets: -38.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.28
• Quick Ratio: 8.28

Sales & Book Value

• Annual Sales: $109.16 million
• Price / Sales: 2.29
• Cash Flow: $0.01 per share
• Price / Cash Flow: 108.27
• Book Value: $1.82 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 181,070,000
• Free Float: 176,729,000
• Market Cap: $249.88 million
• Optionable: Optionable
• Beta: 1.67